Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Dementia in People with Type 2 Diabetes-A Population-Based Cohort Study

被引：0
|
作者：
Tang, Huilin
Shaaban, C. Elizabeth
Wu, Yonghui
Magoc, Tanja
Donahoo, William T.
Dekosky, Steven T.
Bian, Jiang
Guo, Jingchuan
机构：
来源：
DIABETES | 2023年 / 72卷
关键词：
D O I：
10.2337/db23-894-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
894-P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis
    Kristensen, Kasper B.
    Henriksen, Daniel P.
    Hallas, Jesper
    Pottegard, Anton
    Lund, Lars C.
    DIABETOLOGIA, 2021, 64 (07) : 1563 - 1571
  • [42] Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
    Kim, Yoojin
    Babu, Ambika R.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2012, 5 : 313 - 327
  • [43] Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes
    Yanai, Hidekatsu
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (23)
  • [44] Safety of sodium-glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations
    Davidson, Jaime A.
    Sukor, Norlela
    Hew, Fen-Lee
    Mohamed, Mafauzy
    Hussein, Zanariah
    JOURNAL OF DIABETES INVESTIGATION, 2023, 14 (02) : 167 - 182
  • [45] Sodium-glucose cotransporter-2 inhibitors and fractures in type 2 diabetes mellitus
    Pavlicek, Vojtech
    DIABETOLOGE, 2022, 18 (02): : 198 - 199
  • [46] Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering
    Neuen, Brendon L.
    Cherney, David Z.
    Jardine, Meg J.
    Perkovic, Vlado
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (41) : E1128 - E1135
  • [47] DIABETIC KETOACIDOSIS RISK AFTER INITIATING AN SGLT2 (SODIUM-GLUCOSE COTRANSPORTER 2) INHIBITOR: A POPULATION-BASED COHORT STUDY
    Fralick, Michael
    Schneeweiss, Sebastian
    Patorno, Elisabetta
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2017, 32 : S162 - S162
  • [48] Diabetic Ketoacidosis Risk After Initiating an SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitor: A Population-Based Cohort Study
    Fralick, Michael
    Schneeweiss, Sebastian
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 51 - 51
  • [49] The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with gout
    Yokose, Chio
    Mccormick, Natalie
    Abhishek, Abhishek
    Dalbeth, Nicola
    Pascart, Tristan
    Liote, Frederic
    Gaffo, Angelo
    Fitzgerald, John
    Terkeltaub, Robert
    Sise, Meghan E.
    Januzzi, James L.
    Wexler, Deborah J.
    Choi, Hyon K.
    NATURE REVIEWS RHEUMATOLOGY, 2024, 20 (04) : 216 - 231
  • [50] Sodium-Glucose Cotransporter 2 Inhibitors in Cardiovascular and Renal Outcomes in Patients With Diabetes but Without Established Cardiovascular Disease: A Nationwide Population-Based Cohort Study
    Chang, Hao-Chih
    Kuo, Tzu-Ting
    Chen, Yun-Yu
    Lin, Yenn-Jiang
    Chang, Hung-Yu
    Hung, Chung-Lieh
    Chung, Fa-Po
    DIABETES CARE, 2022, 45 (09) : E129 - E130
12345